<DOC>
	<DOCNO>NCT00063310</DOCNO>
	<brief_summary>ALADDIN research study investigate safety effectiveness leuprolide ( hormone drug ) improve cognitive function slow progression Alzheimer 's disease ( AD ) . In woman leuprolide commonly use treat hormone related condition endometriosis uterine fibroid . The study include treatment woman 65 year old mild moderate Alzheimer 's disease reside community .</brief_summary>
	<brief_title>ALADDIN Study : Antigonadotropin-Leuprolide Alzheimer 's Disease Drug INvestigation</brief_title>
	<detailed_description>The study include treatment participant mild moderate AD , objective evaluate safety efficacy two different dos leuprolide improve cognitive function slow progression AD , measure ADAS-COG Clinical Global Impression ( CGI ) . Measures behavioral disturbance quality life caregiver make also . The study design randomize , double blind , placebo-controlled , parallel group design 2:1 randomization drug placebo . Sample size include 90 participant</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Leuprolide</mesh_term>
	<criteria>Patients satisfy inclusion criterion list eligible entry trial . Patients consider eligible : They give consent signing IRBapproved Informed Consent Form responsible caregiver also sign consent form ; , patient judge Investigator unable give consent , legally authorize representative give consent sign consent form patient give assent , accord local regulation ; They female ; They 65 year age old ; They diagnosis probable AD accord National Institute Neurological DisordersAlzheimer 's Disease Related Disorders Association ( NINDSADRDA ) criterion Investigator ascertain condition present least 6 month prior screen ; They take cholinesterase inhibitor , begin take least 90 day prior baseline , Investigator 's opinion , dosage likely remain stable throughout trial ; They take drug substance purport cognition enhance property ginkgo biloba Vitamin E , begin take least 60 day prior baseline , Investigator 's opinion , dosage likely remain stable throughout trial ; They score low 12 high 24 ( MMSE ) administer screen visit ; They brain image study ( CT scan , MRI PET ) perform time initial diagnosis AD time , finding consistent diagnosis probable AD , , brain imaging study perform , one perform screen process ; Their Rosen Modified Hachinski score 4 low screening visit , support Investigator 's clinical judgment patient 's dementia probable AD vascular origin ; They fluent English Spanish complete least 6 year education ; They live home congregate living facility requirement skilled nursing care , caregiver see patient least three time week total least 10 hour sign consent form , provide information pertinent patient 's cognitive status , accompany patient clinic visit participate evaluation ; Their hormone replacement therapy ( HRT ) , , stable least 60 day prior baseline , expect change course trial ; They score less 15 Hamilton Depression Scale ( 17item version ) ( HamD ) administer part screen evaluation ; Absorptiometry ( dualenergy xray absorpometry ( DEXA ) scan ) , perform screening , within normal limit ( i.e. , T score less 2.0 ) ; , DEXA measure abnormally low , receive treatment osteoporosis least 3 week treatment expect change course trial ; , DEXA measure abnormally low receive treatment osteoporosis , may enter trial 3 week treatment provide assessment HamD , concomitant medication , ECG trace laboratory test perform within 45 day baseline show eligible . value screen laboratory test indicate significant medical condition would interfere participation completion study Patients exclusion criterion list ineligible entry study . Patients declare ineligible : They male ; They younger 65 year age ; They significant neurological disease affect brain psychiatric disease AD , major depression , schizophrenia , epilepsy , Parkinson 's disease , stroke ; They current significant systemic illness symptom organ failure ; The screening ECG show evidence serious and/or unstable condition recent ( within 6 month ) myocardial infarction ; They history cancer within last 5 year , except basal cell squamous cell cancer , cervical carcinoma situ ; They take cholinesterase inhibitor ( tacrine , donepezil , rivastigmine , galantamine ) less 90 day prior baseline ; , opinion Investigator , likely either require change dose discontinuation drug They never receive cholinesterase inhibitor treatment likely initiate ; They start change within 60 day prior screen visit dosage drug ( include counter drug ) affect cognitive function , neuroleptic , antidepressant , anxiolytic , sedative , hypnotic , anticonvulsant , centrally act antihypertensive agent clonidine Aldomet ; medication show possible effect cognition Vitamin E , non steroidal antiinflammatory drug , statin , hormone replacement therapy , , Investigator 's opinion , dosage medication likely change course trial . Any change dosage drug course trial reason change must fully record concomitant medication page patient 's case report form ( CRF ) . If drug affect cognition give PRN basis , treatment interrupt 12 hour visit , possible ; They receive coumadin antiParkinsonian medication ; They receive investigational drug within 30 day 5 halflives prior randomization , whichever longer ; They take medication know affect serum gonadotropin ( Gn ) concentration , goserelin danazol , except estrogen and/or progesterone ; They history bone fracture possibly secondary low bone mass density ; They history osteoporosis associate bone fracture unless receive therapy osteoporosis least 3 week , treatment regimen expect stay stable DEXA measure abnormally low ( i.e. , Tscore &lt; 2.0 ) receive treatment osteoporosis least 3 week ; They screen HamD score 15 high ; Their abuse dependence alcohol substance satisfy criterion DSMIV categories 303.9 305 ; They donate blood within 30 day baseline likely course trial .</criteria>
	<gender>Female</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2006</verification_date>
	<keyword>Alzheimer disease</keyword>
	<keyword>Aging Women</keyword>
	<keyword>Hormone therapy</keyword>
</DOC>